FDA nixes wider use of rheumatoid arthritis drug

Courtesy Newsvine - business  Sat, 10/17/2009 - 09:52

The Food and Drug Administration has rejected an application to expand the use of rheumatoid arthritis treatment Rituxan for patients with earlier stages of the disease, biotech drug developers Genentech Inc. and Biogen Idec said Saturday.


 

Related items

FDA clears Genentech drug for kidney cancer
Biotech drugmaker Genentech Inc. said Sunday the Food and Drug Administration approved its cancer treatment Avastin for a new use against a form of kidney cancer, marking the sixth approval...

Mead Johnson Says Its Tests Show Enfamil Baby Formula...
Mead Johnson Nutrition Co. said tests it conducted on samples of its Enfamil baby formula tied to an U.S. Food and Drug Administration investigation found no presence of bacteria.

After-Hours Movers 10/19: (NEOP) (RVBD) (SCSS) (CBST)...
Neoprobe Corporation (NYSE: NEOP) 19.5% HIGHER; today announced that its New Drug Application (NDA) for Lymphoseek has been accepted for review by the U.S. Food and Drug Administration....

Panasonic Dect 6.0 Expandable Silver Digital Cordless...
DECT 6.0 TECHNOLOGY EXPANDABLE UP TO 6 HANDSETS ALL DIGITAL ANSWERING SYSTEM WHITE BACKLIT LCD ON HANDSET CALL WAITING CALLER ID WITH TALKING CALLER ID UP TO 4-WAY CONFERENCE CAPABILITY NIGHT...

Wireless Headset W Adapter for Cordless Telephones
Sound like the Pro you are with the Plantronics CS55H Home Edition Wireless Headset System. It combines the clarity of traditional corded technology with the hands-free mobility of wireless...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
CAPTCHA
We apologize for the inconvenience. Please help fight spam.
business.marc8.com